Royalty Pharma (RPRX) 44th Annual J.P. Morgan Healthcare Conference summary

Key business highlights and strategy

• Achieved 14–16% growth in portfolio receipts for 2025, with strong returns on invested capital (15.7%) and equity (22.9%).

• Internalized external management, reducing costs and improving governance.

• Deployed $2.6B in value-creating royalty transactions, including eight new royalties and a landmark deal with Revolution Medicines.

• Returned $1.2B to shareholders via share repurchases and increased dividends.

• Consistently outperformed analyst expectations in 15 of the last 22 quarters.

Strategic vision and growth objectives

• Aims to be the leading capital allocator in life sciences, targeting consistent, compounding growth.

• Focuses on strong execution, rapid industry growth, and an optimized business model.

• Maintains a dynamic capital allocation framework, balancing royalty investments and share repurchases based on market conditions.

• Projects significant financial capacity, with $30 billion available for strategic initiatives through 2030.

Financial performance and capital deployment

• Achieved 2025 portfolio receipts guidance midpoint of $3.225 billion, reflecting ~15% year-over-year growth.

• Delivered double-digit average annual growth in royalty receipts since IPO, exceeding expectations in 15 of the last 22 quarters.

• On track to meet or exceed the 5-year capital deployment target of $10–12 billion (2022–2026).

• Return on Invested Capital averaged 14.8% annually, with Return on Invested Equity at 21.5%.